OncoMatch

OncoMatch/Clinical Trials/NCT07028086

VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma

Is NCT07028086 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies VAM_GROUP for acute myeloid leukemia.

Phase 2RecruitingRuijin HospitalNCT07028086Data as of Jun 2026Location: China

Treatment: VAM_GROUPThe mitoxantrone liposomal enhances the tissue permeability of mitoxantrone by incorporating liposomal groups compared to the conventional mitoxantrone formulation, while also reducing the concentration of free mitoxantrone, thereby minimizing drug side effects-particularly cardiotoxicity. Building upon this, the investigators aim to investigate the efficacy and safety of the liposomal mitoxantrone hydrochloride injection in patients with secondary AML, AML with extramedullary involvement, or myeloid sarcoma, in order to explore alternative therapeutic strategies for these populations.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

VAM_GROUP

Cancer type

Acute Myeloid Leukemia

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≤ 65

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Lab requirements

Kidney function

serum creatinine ≤1.5x ULN

Liver function

ALT and AST ≤2.5x ULN (≤5x ULN for patients with liver involvement); total bilirubin ≤1.5x ULN

Cardiac function

Normal cardiac function, with LVEF ≥50%

Normal cardiac function, with left ventricular ejection fraction (LVEF) ≥50%; ALT and AST ≤2.5 times the upper limit of normal (ULN) (≤5 times ULN for patients with liver involvement); total bilirubin ≤1.5 times ULN; serum creatinine ≤1.5 times ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07028086 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Is there an age limit?

Yes. Patients must be 65 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify